The Biologic Therapy Core Facility is responsible for:
- Developing and manufacturing novel biologic, cellular and other state-of-the-art therapeutics for human administration under controlled conditions in accordance with the U.S. Food and Drug Administration and other regulations.
- Providing support for translational medicine (from bench to bedside) in the field of cellular therapy, gene therapy and other treatment modalities.
- Providing support and help in the administrative process of getting a therapeutic agent approved by regulatory agencies and finally applied clinically.
- Helping with the production of other therapeutics and products (pharmaceuticals) administered to humans that need to be manufactured in a controlled environment.
- Routine tissue processing and cryopreservation (e.g. cryopreservation of parathyroid tissue).
The Biologic Therapy Core Facility also provides consulting services for Siteman Cancer Center members, Washington University faculty and interested academic and nonacademic entities in compliance with Good Manufacturing Practice rules and regulations, and with issues regarding the new Good Tissue Practice Act, which became effective in May 2005.
For more information, visit the core facility website.
David Curiel, MD, PhD, facility director
William Swaney, MS, operations director
Johnnie Cartwright, MBA, MT, quality assurance
Beverly Gibson, research laboratory supervisor
Heather Missey, senior research technician
LOCATION: Southwest Tower, Room 717; Office: Southwest Tower, Room 719
TO ACCESS: Contact William Swaney at 314-362-9011 or e-mail firstname.lastname@example.org
As of April 7, 2008, the NIH requires investigators with a publication using Siteman (or other NIH-funded) shared resources to submit (or have submitted for them) their final, peer reviewed manuscripts to PubMed Central(PMC) upon acceptance of publication, to be made publicly available within 12 months of publication. Many journals automatically submit these for authors, but Washington University also has assistance available through the Becker Medical Library. Please see http://publicaccess.nih.gov/FAQ.htm#b7 or http://becker.wustl.edu/classes-consulting/specialized-expertise/nih-public-access-policy for more information.
PUBLICATION ACKNOWLEDGEMENT: If research supported by the Biologic Therapy Core Facility results in publication, please acknowledge this support by including the following in your publication(s):
We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Mo., for the use of the Biologic Therapy Core Facility, which provided __________ service. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA91842.